Complete Metabolic Response Assessed by FDG PET/CT to FOLFIRI-Aflibercept in Second-Line Treatment of Metastatic Colorectal Cancer

被引：2
|
作者：
Amrane, Karim [1 ]
Ollivier, Luc [2 ]
Salaun, Pierre-Yves [3 ,4 ]
Metges, Jean-Philippe [1 ]
Abgral, Ronan [3 ,4 ]
机构：
[1] Univ Hosp Brest, Dept Oncol, 2 Ave Foch, F-29609 Brest, France
[2] Univ Hosp Brest, Dept Radiotherapy, Brest, France
[3] Univ Hosp Brest, Dept Nucl Med, Brest, France
[4] Bretagne Loire Univ, EA GETBO 3878, IFR 148, Brest, France
来源：
CLINICAL NUCLEAR MEDICINE | 2019年 / 44卷 / 07期
关键词：
mCRC; FOLFIRI-aflibercept; FDG PET; CT; BEVACIZUMAB; OXALIPLATIN; PATIENT; FOLFOX;
D O I：
10.1097/RLU.0000000000002611
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
FOLFIRI-aflibercept chemotherapy is indicated in second-line treatment of metastatic colorectal cancer (mCRC) after progression under FOLFOX (+/- bevacizumab). Nevertheless, its proven therapeutic efficacy in clinical trials was based on partial responses. And to date, only 2 cases of complete response assessed by CT were reported in literature. We report a complete metabolic response assessed by FDG PET/CT in a 50-year-old woman with mCRC treated by FOLFIRI-aflibercept. This also confirms that FDG PET/CT is emerging as a useful approach for therapeutic assessment of targeted drugs in mCRC.
引用
收藏
页码：578 / 579
页数：2
相关论文
共 50 条
  • [31] Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer
    Suzuki, Takeshi
    Shinozaki, Eiji
    Osumi, Hiroki
    Nakayama, Izuma
    Ota, Yumiko
    Ichimura, Takashi
    Ogura, Mariko
    Wakatsuki, Takeru
    Ooki, Akira
    Takahari, Daisuke
    Suenaga, Mitsukuni
    Chin, Keisho
    Yamaguchi, Kensei
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (02) : 307 - 313
  • [32] Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer
    Takeshi Suzuki
    Eiji Shinozaki
    Hiroki Osumi
    Izuma Nakayama
    Yumiko Ota
    Takashi Ichimura
    Mariko Ogura
    Takeru Wakatsuki
    Akira Ooki
    Daisuke Takahari
    Mitsukuni Suenaga
    Keisho Chin
    Kensei Yamaguchi
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 307 - 313
  • [33] Aflibercept in combination with FOLFIRI for the second-line treatment of patients with metastatic colorectal cancer: Interim safety data from the global Aflibercept Safety and Quality-of-Life Program (ASQoP and AFEQT studies)
    Sobrero, A.
    Bordonaro, R.
    Frassineti, L.
    Di Bartolomeo, M.
    Thomas, A. L.
    Taieb, J.
    Lledo, G.
    Moore, Y.
    Zilocchi, C.
    Ferry, D. R.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S521 - S521
  • [34] Second-line therapy for metastatic colorectal cancer
    Price, Timothy J.
    LANCET ONCOLOGY, 2015, 16 (05): : 476 - 477
  • [35] Second-line management of metastatic colorectal cancer
    Gallagher, David J.
    Kemeny, Nancy
    CLINICAL COLORECTAL CANCER, 2008, 7 (01) : 25 - 32
  • [36] Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer
    Peeters, M.
    Price, T. J.
    Cervantes, A.
    Sobrero, A. F.
    Ducreux, M.
    Hotko, Y.
    Andre, T.
    Chan, E.
    Lordick, F.
    Punt, C. J. A.
    Strickland, A. H.
    Wilson, G.
    Ciuleanu, T. E.
    Roman, L.
    Van Cutsem, E.
    Tian, Y.
    Sidhu, R.
    ANNALS OF ONCOLOGY, 2014, 25 (01) : 107 - 116
  • [37] Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer
    Peeters, Marc
    Oliner, Kelly S.
    Price, Timothy J.
    Cervantes, Andres
    Sobrero, Alberto F.
    Ducreux, Michel
    Hotko, Yevhen
    Andre, Thierry
    Chan, Emily
    Lordick, Florian
    Punt, Cornelis J. A.
    Strickland, Andrew H.
    Wilson, Gregory
    Ciuleanu, Tudor E.
    Roman, Laslo
    Van Cutsem, Eric
    He, Pei
    Yu, Hua
    Koukakis, Reija
    Terwey, Jan-Henrik
    Jung, Andre S.
    Sidhu, Roger
    Patterson, Scott D.
    CLINICAL CANCER RESEARCH, 2015, 21 (24) : 5469 - 5479
  • [38] Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
    Macarulla, T.
    Cervantes, A.
    Tabernero, J.
    Rosello, S.
    Van Cutsem, E.
    Tejpar, S.
    Prenen, H.
    Martinelli, E.
    Troiani, T.
    Laffranchi, B.
    Jego, V.
    von Richter, O.
    Ciardiello, F.
    BRITISH JOURNAL OF CANCER, 2015, 112 (12) : 1874 - 1881
  • [39] A prospective study of FOLFIRI plus aflibercept as second-line treatment after failure of FOLFOXIRI plus bevacizumab in patients with unresectable/metastatic colorectal cancer (CRC): EFFORT study
    Satake, Hironaga
    Ando, Koji
    Yasui, Hisateru
    Negoro, Yuji
    Kinjo, Tatsuya
    Yuge, Koutarou
    Baba, Kenji
    Orita, Hiroyuki
    Hirata, Keiji
    Shimokawa, Mototsugu
    Makiyama, Akitaka
    Saeki, Hiroshi
    Oki, Eiji
    Baba, Hideo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] FOLFIRI3-aflibercept as second- or later-line therapy in patients with metastatic colorectal cancer
    Carola, Candice
    Ghiringhelli, Francois
    Kim, Stefano
    Andre, Thierry
    Barlet, Juliette
    Bengrine, Leila
    Marijon, Helene
    Garcia, Marie Line
    Borg, Christophe
    Dainese, Linda
    Steuer, Nils
    Larsen, Annette K.
    De Gramont, Aimery
    Chibaudel, Benoist
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345